Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 2Myeloid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Sarcoma 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Immunoblastic Lymphadenopathy 3Colorectal Neoplasms 3Burkitt Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Unspecified Adult Solid Tumor, Protocol Specific 2Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neoplasms, Plasma Cell 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Kidney Neoplasms 2Carcinoma, Renal Cell 2

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × Blotting, Western × Clear all
NCT00900055 2022-07-05

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

OHSU Knight Cancer Institute

Completed
213 enrolled
Classical hematologyMyeloidPlasma cell

Fanconi Anemia, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases

NCT00618345 2011-05-16

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Completed
35 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡